Good afternoon. My name is Chantal, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Veeva Systems Fiscal 2017 Third Quarter Results. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. Rick Lund, Investor Relations Director, you may begin your conference.

Good afternoon, and welcome to Veeva's fiscal 2017 third quarter earnings call for the quarter ended October 31, 2016. With me on today's call are Peter Gassner, our Chief Executive Officer; Matt Wallach, our President; and Tim Cabral, our Chief Financial Officer. During the course of this conference call, we will make forward-looking statements regarding trends, our strategies, and the anticipated performance of the business. These forward-looking statements will be based on management's current views and expectations, and are subject to various risks and uncertainties. Actual results may differ materially. Please refer to the risks listed in our earnings release, and the risk factors included in our most recent filing on Form 10-Q, which is available on the Company's website at veeva.com under the Investors section, and on the SEC's website at sec.gov. Forward-looking statements made during the call are being made as of today, November 22, 2016. If this call is replayed or viewed after today, the information presented during the call may not contain current or accurate information. Veeva disclaims any obligation to update or revise any forward-looking statements. We will provide guidance on today's call, but will not provide any further guidance or updates on our performance during the quarter unless we do so in a public forum. On the call, we will also discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A reconciliation to comparable GAAP metrics can be found in today's earnings release, which is available on our website and as an exhibit to the Form 8-K filed with the SEC just before this call. With that, thank you for joining us. And I will turn it over to Peter.

Thank you, Rick. Good afternoon and thanks everyone for joining us today. I'm pleased to share highlights from yet another strong quarter. Total revenue was up 34% year-over-year to $142.8 million. Subscription revenue grew 39% to $113.6 million. And non-GAAP operating margin was 33%. As we've seen throughout the year, our outperformance was driven by strength across all areas of the business. We continued to see Vault momentum increase and growing numbers of customers are moving to commercial cloud. Customers are very successful with Veeva products and we continue to develop new cloud solutions. This cycle of customer success and new products fueled our strong growth in Q3 and positions us well for the future. Let me turn to the highlights in Veeva Commercial Cloud for the quarter. Commercial cloud is an exciting area where Veeva is helping to move the industry forward as companies adapt to new commercial models and unified systems for greater agility and efficiency. The foundations of Veeva Commercial Cloud is core CRM for sales automation where we continue to extend our position as the industry standard. We have multiple significant core CRM projects underway with large pharma companies around the globe. We had a go-live with the top 20 pharma in the U.S. this quarter, marking our first go-live with Veeva CRM. We saw strength internationally as well. Another top 20 expanded into China representing a seven-figure deal. We had a major purchase and go-live in Korea from yet another top 20, making them our largest customer in Korea to-date. We started a significant project for CRM in Japan with another top 20 and a top 50 pharma went live in France. This was their first deal with CRM project as well. We also continued to add many new SMB customers around the world. So,…

Thanks, Peter. Q3 was another strong quarter of consistent execution. Total revenue was $142.8 million, up 34% from $106.9 million one year ago. This was nearly $7 million above the high end of our guidance with a few million of upside from subscription revenue and even more from services revenue. Before I go through the results in detail, it's worth noting that this quarter saw a number of tailwinds across many line items on the income statement. This resulted in an operating margin well in excess of our guidance and not necessarily indicative of how we see margins playing out in the near-term. For the quarter, subscription revenue was up 39% to $113.6 million from $81.7 million last year. Subscription revenue benefited from another strong bookings quarter with particular strength in Vault which as Peter mentioned, slightly exceeded commercial cloud bookings for the first time ever. Services revenue came in at $29.2 million, up 16% from $25.2 million one year-ago. This performance was well above our expectations due to several factors in the quarter. First, there was broad-based demand across the product portfolio, but especially with Vault R&D and international CRM projects. This drove a record utilization during the quarter. Additionally, we benefitted from a fixed milestone payment recognized in the quarter. I expect services revenue to be down roughly $3 million on a sequential basis in Q4 due to the impact of fewer billable days which is in a normal seasonal pattern for our services business. As a reminder, our services revenue can be highly variable for a number of reasons. So, these types of sequential swings may happen from time-to-time. In discussing the remainder of the income statement, please note that unless otherwise stated, all references to our expenses and operating results are on a non-GAAP basis and…

[Operator Instructions] Your first question comes from Bhavan Suri with William Blair. Your line is open.

Congratulations and just a great job there. Just a couple of quick questions. The first, you guys announced a very nice win with ICON. Obviously they are involved with some of the Vault products. But given the relationship that the CROs have with pharmaceutical companies, I would love to understand sort of is there a reseller benefit to this, as they start acting as a channel partner, as they go to do new clinical trials, and what does that trajectory look like. And is that something you could see with other CROs? I wanted to just get some more color on that? Thanks.

Sure Bhavan, this is Matt. So, the way that we go to market in clinical today is not with resellers but as you know that in the clinical markets, some of the other companies that operate here do. So with eTMF and CTMS and Study Startup, I think that we remain in the direct model that seems to be what works for the industry. In EDC, as that business scales, that’s something that we would look at potentially having a different kind of relationship with the CROs, but we haven’t declared any strategy there yet.

Okay, great. Then, one quick follow-up there. CRM growth has been fairly strong. So, despite some of the penetration into seat count, and you seem to have nice adoption there. Just any color on sort of the ARPU growth there, the add-on, sort of which ones are gaining traction? As you think through that, ultimately, let’s assume you captured 70% to 80% of market, what does sustainable growth look there? That will be great. Thank you.

Sure. So, yes, as we’ve said, there is still room to expand the base product. And we saw Peter refer to a few of those big expansions on the call. There is still reason to believe that we will continue to be successful there as we penetrate not just the markets where we’ve been traditionally strong but also in emerging markets over time. Of the add-on products that are doing well, it actually feels like they are all doing well. Approved Email had another great quarter; it’s now used by over 35% of our customers. CLM continues to be used by more than 80%. And then, while the others are doing well, Engage for Portals, Events and Align, there is still only about 5% or less of our customers are using them. So, just a lot of room to grow with those newer add-on products. And then, the Engage Meeting and Engage Webinar that we recently announced at our commercial summit in June, I think has potential to be a really significant growth driver for us as well. If you think of video calling and your ability to use Skype video or FaceTime or your mothers or your friends versus what pharma reps are actually doing in the field, we think there is a big opportunity to increase the efficiency of our customer. So, yes, and we remain as confident as we ever have been in our ability to continue to grow that business over time.

Your next question comes from Richard Davis with Canaccord. Your line is open.

Matt, you kind of said in the past that you want to build or you believe you can build kind of a multi-vertical cloud business. And in that vein, when you step back and kind of think about how you want to build this Company out over the next few years, what are the -- are there any key things that we as outsiders can kind of think about that would help us kind of understand the direction that you might go there other than oh, it’s complicated and is regulated because that's 80% of the economy, sadly to say. So, anyway, thanks very much if you could help me on that. Thanks.

Hi. Richard. This is Peter. I'll take that one. In terms of the multi-vertical, we're really focused on industry cloud for life sciences. And it's a big -- sometimes forget what a big industry life sciences is, 1.7 trillion and industry growing. And we’re still really in the early days of building that out. So, that's really our focus. And if you look at what we are trying to do and what we are good at in making a core competency at is attacking these multiple large markets, simultaneously, building multiple products, selling multiple products and doing that with a lot of discipline. So, that's really our focus. We think we’re early days and we are going to remain focused on industry cloud for life sciences.

Your next question comes from Karl Keirstead with Deutsche Bank. Your line is open.

I’ve got two for Tim. Hey, Tim. First, on the operating margin guide of 27% to 29% for next year, that's roughly flat to up from this year, despite the investments you are going to have to make to capture that new clinical data management opportunity. So, I just wanted to ask you is it that those investments aren’t to owners or -- and I suspect this is the case, the core business operating margins are just really kicking in and enabling you to go after that new opportunity and still keep margins flat? Thank you.

I think it's a combination of the two. I think as you -- and we talked a little bit about this, I think it was in the last call as it relates to the efficiency we’re seeing given the fact that we have the unified suite in the Vault platform and the ability to invest very efficiently in that area. And then, I think you are right, the other areas within the business in an industry cloud model were benefitting from the industry cloud model and the efficiency that that has from a margin perspective.

Okay, that makes sense. And maybe this is a related question but in terms of your OpEx performance, what struck me is your sales and marketing expenses were roughly flat in terms of dollars for three consecutive quarters despite the growth in the business. Tim, you talked a little bit about some of the one-off reasons why in the third quarter you got good sales and marketing leverage. But, just if you could expand on that and help us understand whether there is any unique sources of sales and marketing leverage that are now kicking in?

Yes. I wouldn’t say there is any new or unique sources, Karl, of sales and marketing leverage. I think when we look at the set up of sales in marketing from a quarter-to-quarter perspective, there are some things that can create that flattening or lumpiness. And those things, as you know, are commissions, those are large customer events which as you know we have our largest customer event in Q2 which took our marketing programs spend up in Q2 and we didn’t have that same type of or size of event in Q3. So, there is a number of things that could drive the direction of that. But again, back to your original question, I think the underlying industry cloud sales and marketing efficiency that we’ve seen over the course of the number of years continues to be the primary driver to that sales and marketing model.

Okay, good. Congrats Tim on that fantastic OpEx control.

Your next question comes from Kirk Materne with Evercore ISI. Your line is open.

Tim, I have a question on hiring plans. Obviously, you guys got off to -- you hired a lot of people at the beginning of this year. Can you just give us some thoughts on how you are thinking about fiscal 2017 -- fiscal 2018 rather in that regard, more frontend loaded, is that going to be the way we should be thinking about that going forward? And then, just secondly, any broader thoughts on M&A, as you guys look at across industry and places where you could -- from our angle try to figure out if there is a lot of smaller tuck-in opportunities for you all? Matt, if you want to talk about that. But I am just kind of curious if we should consider M&A sort of a broader part of the use of cash going forward as well, Thanks.

Kirk, let me tackle the headcount question and then I'll hand it off to Matt on the M&A side. In terms of headcount, as you said, we have continued to invest aggressively from a headcount perspective across a number of the new products and markets as well as the existing set of products we have. So, a very large product portfolio. And as Peter talked about earlier, we are going after multiple large markets in this life sciences industry. So, we will continue to do that. In terms of the flavor for FY18, we will give a little bit more flavor on that on our next call, Kirk. But I would say in general, we continue to invest aggressively against what we see as a large market opportunity in front of us. Matt?

Yes. And then, in terms of M&A, really no change in our strategy, despite what is a pretty significantly growing cash balance. I think we will be opportunistic as things appear. And there is a lot for sale in the life sciences space right now. But we are not pursuing anything that is significant. I think the other thing that is maybe affecting that a little bit is the strength of the Vault platform is becoming more and more clear to us and to our customers. And so, the chances that we buy a small company with a product and keep that product around has probably gone down over time as the Vault platform has looked like a better and better place for us to expand, particularly within life sciences in the areas that we are competing today. And so the overall strategy of M&A to bolt-on, product knowledge and experts and customer relationships that remains -- that really hasn’t changed at all.

Your next question comes from Stan Zlotsky with Morgan Stanley. Your line is open.

One thing that really stood out to us, is the number of exciting go-lives from big customers that we heard outside of the U.S. Is there something specific that’s driving adoption in those geographies. And then a follow-up question. What kind of pricing are you seeing for these products in those geographies compared to what you see for the same products within the U.S. And I have a quick follow up for Tim.

Actually there was nothing really extraordinary about the last quarter. As we looked at some of the highlights of the quarter, these stood out may be a little bit more then they have in the past. But, if we had given this kind of color, when these big deployments happened outside the U.S. every quarter, we would have been talking about it for the past 8 or 9 or 10 calls. The thing that was different, was may be the size of one of these deployments increase that was the biggest we’ve seen; the size of the one in China was very large but we have a bunch of others. So, nothing really changed there. Some of them were brand new competitive displacement wins and some of them were just expansions of existing custom during global projects. In terms of the pricing, the pricing differential between U.S., Europe, Japan versus these other markets, has stayed relatively the same since we really started outside the U.S. And so, we model generally about a third less for market outside of there and there is a little bit of variability whether it’s China or it’s Southeast Asia. But that’s generally what we’ve seen in terms of a price differential. And that’s on the base CRM product.

Okay, perfect. Thank you. And just for Tim, anything on FX-related and on billings in the quarter, I know it’s usually not much of an impact, but just wanted to double check?

Yes, Stan. That continued to be immaterial this quarter.

Your next question comes from Tom Roderick with Stifel. Your line is open.

So, let me for this first one at Peter and Matt, I think you guys have historically done a good nice job of weighting for customers to express pain points before entering new markets. And I guess in that vein, what is the primary pain point you want investors to understand, as they think about where you can solve problems for your customers in the clinical data market particularly with your EDC and eSource initiatives? And maybe piggybacking on the earlier question, is that an area where you can utilize M&A to accelerate your efforts?

Okay. Tom, I will take that one. I guess in terms of things to understand about clinical data management, I would say the start off, just to know it’s a large and critical area for life sciences. This is a key part of overall clinical trial processes collecting the clinical data from the patients and managing that data. So, if you look at EDC and eSource, it’s $1 billion market to track for innovation. Now, you asked one question about acquisitions there and that’s whether we would look to use that as a strategy or boosting. Not really there, I think that we may augment on some things for some particular talent. But the core part of our strategy is really the same. We do it the same as we've done it for other markets. We assembled the best team of really experienced, the best, A team in that area. We build it on the Vault platform. We get a lot of leverage there we execute in the field, get our early adopters and our customer success and then we take the long-term view. I guess in terms of EDC also, I think it's important to know that we can leverage our existing focus in eTMF and CTMS and Study Startup all in the common platform because that's very relevant and has to be integrated with EDC. So, in terms of clinical data management, it's a good example of how we go into a market. In this market, absolutely customers were asking us say -- they are pulling us into that market. And we won't go into every market that customers pull us into because we have to be disciplined in our approach. But, when customers are pulling us into a market and we think there is room for innovation, and we think the market is of the right size, then we target it and we go in there. And then we do it right assembling the A team. So that's how we look at the EDC market and also at picking markets in general.

Perfect. Tim, a quick follow-up for you. You gave some guidance initially here for fiscal 2018. How would you suggest we think about the ramp, the growth trajectory for services, kind of a similar rate to this year, will that continue to slowdown just a little bit just thinking about the mix in revenue for next year, any directional guidance here for us would be great? Thanks.

Yes, Tom. I think for now, I'll keep it at the high level and will give a little bit more color as we typically do in our Q4 call. So I'll leave it at that.

Your next question comes from Ken Wong with Citigroup. Your line is open.

Hey, a couple of questions on my end. So, kind of back to the operating margin range with 27% to 29%, I can’t help, but in Q4 it’s 28%. So, should we expect that we get a dip down from the 28% or even the 27% linearly moves up to somewhere in the midpoint of that range or is it going to be I guess kind of a more flat trajectory as we think about how to model that out?

Well, I think the one thing you can into account, Ken, is there is some seasonality from a number of revenue days that you know from us that Q1 is different than Q2, Q3 and Q4. So, I think that's probably the most simple additional color I would give. I would say that we wanted to give a little bit of early guidance and we've done that. We will certainly give more color in our next call in 90 days from now.

Okay, that's fair. And then, you mentioned shorter invoice duration. Is that a trend that you've been seeing or is that just again kind of a one-off Q3 type of an issue, not issue, but occurrence?

Yes, I would say that. We actually saw the opposite and we talked a little bit about that in Q1 and Q2, as we saw the renewal day shift into those quarters and some of the renewals and add-on orders would have longer duration. Q3 is becoming the seasonal low as it relates to our renewal base, Ken. And therefore, when we do see add-on orders that are new ACV or new bookings related, those are very short in durations. The other thing that is maybe just specific to this Q3 Ken is that the mix of the bookings was a little bit more to customers that actually have quarterly billing terms as opposed to annual billing term. So, it was a combination of those two that drove shorter invoice duration. I would say the first one, you could loosely characterize as seasonal. I would say the second one is just the mix of the particular booking to the particular customers in this Q3.

Your next question comes from Scott Berg with Needham. Your line is open.

I guess two quick questions for me is I think both Peter and Tim called out the strength in the Vault business on the R&D side of the ledger here in the quarter, but how should we think about the commercial side of the business. Obviously, we know CRM penetrates are getting little bit higher but are there ways to expand or I guess accelerate those revenue growth while you are seeing maybe on Vault Commercial or maybe some of the other newer CRM products that have been released recently?

Yes, Scott, this is Matt. So, Vault Commercial doesn’t tend to get a whole lot of airtime on our call. So, thank you for calling it out. So, we had the Zinc acquisition about 14 months ago. The premise was that commercial content was going to be very important, as our customers move more into a digital world and that by acquiring the Zinc business, we could combine those teams, our technology experts, their regulatory and content experts and create something even better for our customers. So, I am happy to report that I think the strategy was right, the reasons for the acquisition were right and I think that we have seen great results, both in terms of a better product taking the Veeva product experts together with the deep domain experts from Zinc, has created a better product. Our customers have been very pleased including those that have migrated from the Zinc product to the Vault PromoMats product. And we have even expanded the breadth of the solution for our largest customers with the addition of digital asset management capabilities which will for really all of our customers eliminate another system that they would have had to integrate to something like Vault or Zinc in the past. So, it's really been very successful. We added more customers there last quarter than maybe I think we ever did in a single quarter before. So, we are really the market leader in commercial content, the Zinc acquisition feels like a big success. And I think that it's going to continue to be a strategically important part because of the deep integration with CRM and all of the multi channel investments that we are making and we see the industry making in the future.

Great. Then, one follow-up for me would be on the international strength in the quarter that Tim called out in his remarks. How should we view the international strength. Is this still more of a CRM expansion of existing customers, maybe other area those commercial products or is the strength there in the quarter reflective of the Vault strength that you’re seeing domestically in the business today.

I think it's both, internationally. I think primarily, probably the biggest part of that is CRM that core based CRM expanding internationally as part of global programs, our local decisions. But it's also Vault and it is Vault on both sides on R&D and on the commercial. Particularly on the R&D, it’s interesting we’re getting early transaction for R&D Vault in Japan, and commercial Vault also in Japan and other regions. So, truly a mix of both. It was a great quarter for our international parts of Veeva.

Your next question comes from Sterling Auty with J.P Morgan. Your line is open.

I want to start with the significant upside in subscription revenue, did any of the go-lives or implementations actually happened either earlier in the quarter or even a quarter early than you may have expected?

No, Sterling...

Matt and I talking out each other. No, I think nothing unexpected. We have many customers, hundreds of customers now and 12 products overall. So, there is lot of different points, subscription revenue points, but there was nothing, no one thing that came in early or late that slated. It was just overall strength of the business. We had a good bookings quarter, both in Vault and commercial cloud and I think some of those came in slightly earlier than the quarter than we expected.

Yes, Sterling, I think, obviously -- this is Tim. We had three quarters in a row now or actually four if you include Q4 of last year of very strong bookings which has helped our subscription revenue growth. We’re seeing broad based demand across the portfolio. Vault is -- it’s clearly one to call out as Peter and I both did in our prepared remarks. And as of now Vault actually represents -- in the quarter, represented a third of our revenue which is even up from when we talked about at the analyst day. So, just continued strong performance across the entire portfolio. I think it’s driven that subs revenue performance.

And then, you made a comment about, maybe some additional quarterly billings customers in the quarter. Was there any comments read in terms of the size of those customers or any other commonality that would have driven more quarterly versus annual?

Well, I think Sterling for us to mention -- and you want to assume that they are amongst our largest customers, if you will. So, it really again in Q3 or in any quarter it really depends on the mix of those new bookings. As you can imagine, in the billings, the biggest component is our underlying renewal base. But the other component that will swing quarter-to-quarter, some movement in the new bookings. And it just happened that in Q3, the new bookings there was good percent of it that was going to customers that had quarterly billing.

But again, I guess, I’m just curious out of that new that was choosing quarterly, you’re saying that these are bigger customers or bigger companies, I just would have figured maybe that would have been smaller may be in more volume?

Yes Sterling, I’m sorry. What I meant to say was the add-on orders to some of our bigger customers that have quarterly billing already were contributing to our bookings in Q3. So, this is not a new customer choosing quarterly over annual; for the most part, it was add-on orders to existing arrangements that we have with some of our larger customers that happen to have quarterly billing. Does that make sense?

That makes more sense. And then, last question is looking at the product launches that you've got coming, how should we think about the incremental spend, either on infrastructure costs or launch costs and how they should get layered in from a timing perspective, given the April launches and then a launch further later in the year.

Well, I'll take that one. This is Peter. I think that the spend for that is not something we really need to plan for; it's all baked in, in our plan, and there won't be any dramatic spending events. So, I think in that way, it's sort of business as usual for the new products, nothing out of the normal.

Yes, and Sterling that the reason for that is because when we launch a new product, we don’t try to sell it to the whole world. We focus in on early adopters, we get those early adopters live and happy and then over time will sell into additional regions or additional segments of the market. And so, there is no big bang for us the day a product becomes available, not from a marketing or sales perspective.

Your next question comes from Brian Peterson with Raymond James. Your line is open.

Tim, quick one for you. Just on the services strength., obviously it's been much stronger than we expected the last few quarters. Just want to understand, is there anything in particular about these customers, products, international markets that's driving that? And at a certain point, will we see that revenue stream kind of step off to the partners over time?

Brain, thanks for the question. We certainly have a very strong ecosystem of partners across all the regions that we work with our customers. And so, I think over time, over the long run, yes, we will continue to see that as we've seen in that last couple of years. In terms of last couple of quarters, I think what you are seeing is the continued demand across our product portfolio and the different opportunities and some of the new deployments we have across the portfolio. So, I think that’s really what's been driving our services margin outperformance -- or excuse me, our service revenue outperformance. And obviously, in Q3 that materially impacted our services margin.

Got it, understood. And obviously with the Vault booking strength, just curious as we look out to next year, is there anything that is qualitative [Indiscernible]?

Brain, I'm sorry. You are breaking up. Sorry, Brain. Go ahead ask your question.

Yes. So, just trying to get a sense of revenue visibility next year, given the bookings strength and how that's compared to prior years?

Yes, I think the guidance, the early guidance that we gave in this quarter was just that we’ll certainly give more guidance as we've done in the past after we announce our Q4 results in our call 90 days from now.

Your next question comes from Brent Bracelin with Pacific Crest Securities. Your line is open.

Good afternoon. Peter, perhaps I'll start with you here. You just spent a lot of time with customers at the Veeva R&D summit. What did you learn about the appetite within life sciences to spend on kind of modernization projects you think about next year in cloud? What was surprising, either from a Company specific standpoint or even industry standpoint that you learned coming out of event? And then I have one follow-up for Time.

It was a great event, it was about 650 people. You always are optimistic when you go to event of that many people but you never know exactly until you are at the event, how do these people react together. And it was just refreshing again the optimism, the openness, the sharing with Veeva and that people are really appreciative of Veeva, putting serious effort into software for their specific needs and on a common platform. So, this feeling that hey we are doing this together, Veeva is making professional software applications for them. So, that was truly a great feeling. And I would say then the other one is we knew there was a lot of interest in the regulatory area. But I think this event really confirmed that. There is really -- people are really looking at Veeva’s regulatory suite, our RIM suite as pretty groundbreaking and able to accomplish things that they weren’t able to accomplish before. And I think people are looking at that. Regulatory area is a way to drive incremental revenue for their companies by being more efficient and effective in their product registrations, and their planning. So, those are probably the two big macro level takeaways that I had from the R&D customer summit.

And then, Tim, just last question for me here, you mentioned evolved now, a third of the business from a revenue standpoint. I think you talked about it being now over 50% of bookings for the first time. As you think about the composition of Vault, how much of that is just Vault maturing. And so you are now saying the larger Vault customers, the top 20 now sort take Vault versus just an increased number of Vault adoption by your existing customers, multi-Vault can adaption. What's the key driver if you think about that mix shift?

I'll take that one. This is actually Peter. The key drivers are -- you can -- we have hundreds of customers now, and we have 12 Vault applications. So, it’s breadth of many customers and many applications and many segments of the market all the way from the SMB to the large enterprise. So, I said in my remarks now, people are starting to ask why not Vault. And that’s why we are getting good win rates and we are getting lots of that back because we have broader product portfolio than we have had before. And I think we are actually proven on both ends of the market. We are proven that we can -- we have many, many small customers, even less than 200 employees using Vault in certain areas and happy about it and telling others. And then we have many companies where they have in excess of 20,000 employees and they are happy and live with Vault and just reference for both the other similar size company. So, we’re just meeting a sweet spot where we have the products and the referenced customers that meet the needs across multiple touch points.

Your next question comes from Jesse Hulsing with Goldman Sachs. Your line is open.

You had quite a bit of early success with QMS. And I’m wondering as you look to next year and in the long term with the new clinical products, how should we think about, I guess the curve of those product cycles? Do you expect them to take off like QMS did, do you expect it to be a slower ramp in that market, what are your thoughts there?

Sure, this is Matt. It’s a good question, Jesse. So, QMS is certainly kind of hitting a sweet spot, and it’s largely been sold to smaller companies that didn’t have a QMS before. So, it’s companies kind of getting large enough, they need a QMS, if they have QualityDocs, these are very short sales cycles, it’s a very logical extension for them. But we even had a couple of companies where, QMS was the first thing that they bought from Veeva. And so, clearly a lot of success there. We look at CTMS, CTMS is so close to eTMF that we may see a similar flurry of activity at the beginning. But I think it would also be with smaller companies. And we’re generally going to be looking at smaller companies to be the early adaptors. We won’t be ready to do a 5,000-user CTMS deployment at a top 10 pharma with the first version. EDC is a little bit different where it’s not as close to eTMF. So, if you look at the more than 120 eTMF customers, the integration to EDC actually generally it sort of goes through CTMS, not exactly but it’s not a terrible way to think about it. And it’s a little bit of a different buyer. And so, the CTMS buyer is more like the eTMF buyer, the EDC buyer is a little different. And so that might be a reason why that would go a little more slowly. But that sort of customer count, if you think in terms of revenue, these are all going to be similar because the focus isn’t on revenue right when we launch a product, the focus is on getting those early adopters live. And so, I wouldn’t worry about modeling how much revenue is there going to be from a Veeva products in its first year, because we’re not focused on that. We’re focused on making sure the product works, making sure that early adopters are happy and then at the right pace, we’ll start to expand the sales and marketing effort over time.

Got it. That’s helpful. And then, you guys touched on M&A earlier but you do have a lot of cash, you generated almost $150 million in cash so far this year. Can you -- and at the same, you’re also successfully expanding the new markets while driving leverage. So, I’m wondering what your plans are from a use of cash point of view as you look forward and as the business continues to grow?

Yes, Jess, this is Tim., I think the use of cash explanation really hasn’t changed probably over the last 12 months. We continue to work with very large and strategic customers and want to make sure that we show a strong balance sheet, as they partner with us and continue to increase that partnership with us. So, that’s number one. And I think as you’ve seen over the last couple of years, when we can use our cash reserve for strategic M&A whether that’s tuck-in types of opportunities or even an opportunity the size of Zinc which we did 14 months ago, we have the power to do that from a cash prospective. So, I think that’s the primary thinking around how we will use our cash and/or why we want to continue to have such a strong balance sheet.

Your next question comes from Brad Sills with Bank of America Merrill Lynch. Your line is open.

Just one on the commercial business just within CRM expansion deals. Could you provide a little color on how that business tracked in terms of new users versus add-on products like territory alignment multichannel CRM, just some of the add-ons versus just kind of seed expansion within the core CRM business please? Thank you.

Sure, Brad. The quarter, I think was more of the same as what we've seen throughout the year. The majority of incremental revenue came from new users while there was still growth in each of the add-on products. And I think that there is still a few more quarters of that before it switches and we actually get more incremental revenue from the add-on products. But we’re certainly on the path to getting to that point.

Got it, great. And then one more if I may, please. Your sales and marketing leverage has been remarkable as you kind of go into some of these new departments. Is there any one area whether it's clinical or regulatory or quality that you could say well that effort’s gone better from a go to market standpoint but the sales people that we have and we might have expected or maybe there is some that you feel are little bit behind from that perspective but you see upside going forward?

Yes. I mean, I think none really stick out, as you are saying that question. If you look at our sales people, they generally will come with one area of expertise, clinical quality or regulatory. But the sales person him or herself is just one part of the overall sales process. We have strategy people that are experts in every one of these specific areas. And that's probably why it doesn’t stick out that is one area or another that we have 22 products now, 10 on the commercial side and 12 Vault products. We have people in the Company whose only job is each one of those 22 products. And with that kind of focus, we're able to bring the right people and the right messaging and the right understanding of the customers problem into each and every meeting. And so that takes a little bit of the owners off at the sales person, him or herself to be the expert in every single thing that we sell.

Your next question comes from Ben Rose with Battle Road Research. Your line is open.

Matt, question for you regarding the go to market strategy on the clinical side with the addition of EDC and so forth. How large could you see the size of the sales force specifically focused on that products grow to perhaps by the end of this coming year?

So, we generally have not split out the number of quota carrying sales reps by product. What I would say is we are going to supplement the sales team for clinical data management because there is a different buyer there. But, if you follow the company over time that doesn’t mean a 100 sales people. That might mean dozens over time but it's not 100. So, there is nothing about the Veeva way, the way that we have attacked new markets that is fundamentally different in clinical data management, even though it's a very large market opportunity.

Your last question comes from Rishi Jaluria with JMP Securities. Your line is open.

Hey, guys. Thanks for squeezing me in. It's nice to see momentum in the business continue. Two quick ones. First, I guess touching on earlier question, how is the software spending environment from life sciences and specifically pharma customers trended over time and do you maybe see potential for expanding IT budgets from pharma clients, given the potential from maybe a less strength and expected regulatory environment going forward? And then, I have one follow-up.

So, I guess the highest level numbers that we have is the IDC and the total IT spending, and that has actually increased 1 billion or more, I think 3 billion since our IPO. So, the revenue in pharma and life sciences in general has gone from 1.6 trillion to 1.7 trillion in the last three years and the R&D spending I think has gone for $52 billion to $55 billion. And we feel that. Some of it -- and the thing that I think we feel the most specifically is the shift in dollars from capital and kind of on-premise software and big one-off projects to more of operating expenses like the subscriptions that we sell. I think if you would talk to a pharma CFO who is focused on IT expenses, they would probably talk about that shift from capital to operating expenses or capital operating dollars. And then, the question of whether this continues, I think the industry is more dynamic and has changed more rapidly in the last three years than in the last 15 years combined. And so some of these breakthroughs and technology and adapted clinical trials in genomics and digital disruption on the commercial side, I think that people know that IT is going to be a more and more strategic part of growing a successful life sciences company over time. So, I wouldn’t be surprised if budgets continue to increase as the role of IT becomes less tactical and keeping the lights on and much more strategic, getting products to market faster and selling and marketing them more efficiently.

And Tim, quick one for you. So, operating cash flow outperformed this quarter, and I know the dynamics you talked about operating margin but looks like there was kind of also big benefit from collections on the accounts receivable side. I guess can you help us to understand the dynamic here and how we should be thinking about from the medium modeling perspective cash flow going forward? Thank you.

So, I think couple of high level points. Number one, when you look at our underlying renewal base which is the biggest driver to billings that is primarily seasonal in Q4 and early Q1. So, billings typically will be the highest in Q4, little bit of contribution in Q1 from a billings perspective. From a cash flow perspective and you can see that from our performance this year over the first three quarters and in the guidance that I gave. For cash flow, Q1 is going to be our largest quarter as long as that underlying renewal base stays where it is today with Q2 and Q3 being good and Q4 being our trough quarter. So that’s probably the way you want to think about your model from a cash flow perspective.

There are no further questions at this time. I'll now turn the call back over to Peter Gassner.

Thank you, Operator. I would like to thank everyone again for joining us today and a special thanks to the Veeva team for your great commitment and execution as well as to our customers for their continued support and partnership. We look forward to speaking with you again on our fourth quarter call. Thank you.

This concludes today’s conference call. You may now disconnect.